

4/5/2
DIALOG(R) File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.

009565129

WPI Acc No: 1993-258677/199332

XRAM Acc No: C93-114920

New therapeutically active fusion proteins - comprising active polypeptide linked to albumin (variant)

Patent Assignee: RHONE POULENC RORER SA (RHON); FLEER R (FLEE-I);

FOURNIER A (FOUR-I); GUITTON J (GUIT-I); JUNG G (JUNG-I); YEH P (YEHP-I)

Inventor: FLEER R; FOURNIER A; GUITTON J; JUNG G; YEH P

Number of Countries: 022 Number of Patents: 007

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9315199	A1	19930805	WO 93FR85	A	19930128	199332 B
FR 2686899	A1	19930806	FR 921064	A	19920131	199344
FI 9403563	A	19940729	WO 93FR85	A	19930128	199437
			FI 943563	A	19940729	
NO 9402839	A	19940922	WO 93FR85	A	19930128	199442
			NO 942839	A	19940729	
EP 624195	A1	19941117	EP 93904129	A	19930128	199444
			WO 93FR85	A	19930128	
JP 7503368	W	19950413	JP 93512986	A	19930128	199523
			WO 93FR85	A	19930128	
US 5876969	A	19990302	WO 93FR85	A	19930128	199916
			US 94256927	A	19940728	
			US 97797689	A	19970131	

Priority Applications (Nc Type Date): FR 921064 A 19920131

Cited Patents: 1.Jnl.Ref; EP 413622; JP 3201987; WO 8902922; WO 9013653; WO 9300437

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9315199	A1		67	C12N-015/12	
				Designated States (National): CA FI JP NO US	
				Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	
FR 2686899	A1		35	C12P-021/02	
EP 624195	A1 F			C12N-015/12	Based on patent WO 9315199
				Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE	
JP 7503368	W			C12N-015/09	Based on patent WO 9315199
US 5876969	A			C07K-014/00	Cont of application WO 93FR85
					Cont of application US 94256927
FI 9403563	A			C12N-000/00	
NO 9402839	A			C12N-015/62	

Abstract (Basic): WO 9315199 A

New recombinant polypeptides (I) comprise an active portion derived from a therapeutically active polypeptide (II), genetically coupled to an albumin or albumin variant.

Also claimed are: (1) a nucleotide sequence coding for (I); (2) an expression cassette comprising a sequence (1) under the control of a transcription initiation region and opt. a transcription termination region; (3) a self-replicating plasmid contg. a cassette (2); and (4) a recombinant eukaryotic or prokaryotic cell contg. a sequence (1),

cassette (2) or plasmid (3).

USE/ADVANTAGE - (I) are plasma-stable forms of (II) and may be used for the same therapeutic purposes. They may have enhanced activity and/or reduced side effects. The nucleotide sequence may also be used for gene therapy

Dwg.0/18

Title Terms: NEW; THERAPEUTIC; ACTIVE; FUSE; PROTEIN; COMPRISE; ACTIVE;
POLYPEPTIDE; LINK; ALBUMIN; VARIANT

Derwent Class: B04; D16

International Patent Class (Main): C07K-014/00; C12N-000/00; C12N-015/09;
C12N-015/12; C12N-015/62; C12P-021/02

International Patent Class (Additional): A61K-037/02; A61K-038/16;
A61K-038/21; C07K-013/00; C12N-001/19; C12N-001/21; C12N-005/10;
C12N-015/14; C12N-015/81; C12R-001-85

File Segment: CPI